Longer Adjuvant Imatinib Therapy Better in High-Risk GIST - 100285

Spotlight
Video

Longer Adjuvant Imatinib Therapy Better in High-Risk GIST

feeds has 409 videos Subscribe Here

Loading........
Description: Extending the duration of adjuvant imatinib therapy markedly improves outcomes in patients with resected gastrointestinal stromal tumor (GIST) who are at high risk for recurrence, a study presented at the American Society of Clinical Oncology (ASCO) annual meeting suggests.
Shared By : feeds
Posted on : 06/07/11
Added : 7 years ago



More From feeds

Nothing found.